Effect of Long-term Fenofibrate Therapy on Serum Creatinine and Its Reversibility in Hypertriglyceridemic Patients with Hypertension
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Previous studies have shown that fenofibrate therapy increases serum creatinine level and that there is a returnof serum creatinine to baseline level after the discontinuation of the drug. We evaluated the effect of long-term fenofibratetherapy on creatinine levels and its reversibility in patients with hypertension and hypertriglyceridemia. Methods: This retrospective study enrolled 54 hypertensive and hypertriglyceridemic patients taking fenofibrate for 3-6years (Fenofibrate group) and 30 control patients with similar age, sex, follow-up duration, and creatinine levels (Controlgroup). In 23 patients taking fenofibrate with low triglyceride level and/or with high creatinine levels, fenofibrate was discontinued,and creatinine levels were measured after 2 months. Results: Creatinine levels increased in both the fenofibrate group (from 0.91±0.18 mg/dL to 1.09±0.23 mg/dL, p<0.001)and the control group (from 0.94±0.16 mg/dL to 0.98±0.16 mg/dL, p=0.04) compared to baseline. However, the elevationwas more pronounced in the fenofibrate group than in the control group (21.1±15.4% vs. 4.5±11.3%, p<0.001). Thediscontinuation of fenofibrate lowered creatinine levels (from 1.39±0.32 mg/dL to 1.15±0.24 mg/dL, p<0.001) whichwere still higher than pre-treatment levels (p=0.013). Conclusion: Long-term fenofibrate therapy significantly increased creatinine levels in hypertensive and hypertriglyceridemicpatients. The effect of fenofibrate on creatinine level was partially reversible. This finding suggests that follow-up creatininelevel is necessary with fenofibrate therapy. (J Lipid Atheroscler 2017 December;6(2):89-96)
Abstract
Objective: Previous studies have shown that fenofibrate therapy increases serum creatinine level and that there is a returnof serum creatinine to baseline level after the discontinuation of the drug. We evaluated the effect of long-term fenofibratetherapy on creatinine levels and its reversibility in patients with hypertension and hypertriglyceridemia. Methods: This retrospective study enrolled 54 hypertensive and hypertriglyceridemic patients taking fenofibrate for 3-6years (Fenofibrate group) and 30 control patients with similar age, sex, follow-up duration, and creatinine levels (Controlgroup). In 23 patients taking fenofibrate with low triglyceride level and/or with high creatinine levels, fenofibrate was discontinued,and creatinine levels were measured after 2 months. Results: Creatinine levels increased in both the fenofibrate group (from 0.91±0.18 mg/dL to 1.09±0.23 mg/dL, p<0.001)and the control group (from 0.94±0.16 mg/dL to 0.98±0.16 mg/dL, p=0.04) compared to baseline. However, the elevationwas more pronounced in the fenofibrate group than in the control group (21.1±15.4% vs. 4.5±11.3%, p<0.001). Thediscontinuation of fenofibrate lowered creatinine levels (from 1.39±0.32 mg/dL to 1.15±0.24 mg/dL, p<0.001) whichwere still higher than pre-treatment levels (p=0.013). Conclusion: Long-term fenofibrate therapy significantly increased creatinine levels in hypertensive and hypertriglyceridemicpatients. The effect of fenofibrate on creatinine level was partially reversible. This finding suggests that follow-up creatininelevel is necessary with fenofibrate therapy. (J Lipid Atheroscler 2017 December;6(2):89-96)
참고문헌 (22)
- Shah A, "The effect of PPAR-alpha agonism on apolipoprotein metabolism in humans", Atherosclerosis, 210, pp.35~40 (2010)
- Kim CJ, "Management of hypertriglyceridemia for prevention of cardiovascular diseases", J Lipid Atheroscler, 2, pp.53~60 (2013)
- Davidson MH, "Safety considerations with fibrate therapy", Am J Cardiol, 99, pp.3C~18C (2007)
- Lageder H, "Comparative double-blind investigation of bezafibrate and clofibrate in patients with primary hyperlipoproteinaemia", Wien Klin Wochenschr, 92, pp.95~101 (1980)
- Dick TB, "Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia", Curr Med Res Opin, 7, pp.489~502 (1981)
- Rössner S, "Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate", Atherosclerosis, 38, pp.273~282 (1981)
- Diabetes Atherosclerosis Intervention Study Investigators, "Effect of fenofibrate on progression of coronaryartery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study", Lancet, 357, pp.905~910 (2001)
- Keech A, "Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2diabetes mellitus (the FIELD study): randomised controlled trial", Lancet, 366, pp.1849~1861 (2005)
- ACCORD Study Group, "Effects of combination lipid therapy in type 2 diabetes mellitus", N Engl J Med, 362, pp.1563~1574 (2010)
- Messerli FH, "Essential hypertension", Lancet, 370, pp.591~603 (2007)
- Hopkins PN, "Hypertension, dyslipidemia, and insulin resistance: links in a chain or spokes on a wheel?", Curr Opin Lipidol, 7, pp.241~253 (1996)
- Broeders N, "Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?", Nephrol Dial Transplant, 15, pp.1993~1999 (2000)
- Hottelart C, "Fenofibrate increases creatininemia by increasing metabolic production of creatinine", Nephron, 92, pp.536~541 (2002)
- Ritter JL, "Fenofibrate-induced elevation in serum creatinine", Pharmacotherapy, 21, pp.1145~1149 (2001)
- Deighan CJ, "Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease", J Am Soc Nephrol, 12, pp.341~348 (2001)
- Ansquer JC, "Effect of fenofibrate on kidney function:a 6-week randomized crossover trial in healthy people", Am J Kidney Dis, 51, pp.904~913 (2008)
- Brancati FL, "Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial", JAMA, 278, pp.2069~2074 (1997)
- Ritz E, "Nephropathy in patients with type 2diabetes mellitus", N Engl J Med, 341, pp.1127~1133 (1999)
- Davis TM, "Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD)Study", Diabetologia, 54, pp.280~290 (2011)
- Williams AJ, "The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia", Br J Clin Pharmacol, 18, pp.361~367 (1984)
- Angeles C, "Fenofibrateassociated reversible acute allograft dysfunction in 3renal transplant recipients: biopsy evidence of tubular toxicity", Am J Kidney Dis, 44, pp.543~550 (2004)
- Dierkes J, "Serum homocysteine increases after therapy with fenofibrate or bezafibrate", Lancet, 354, pp.219~220 (1999)